TORONTO, ON / ACCESSWIRE / April 24, 2017 / CardioComm Solutions, Inc. (TSX-V: EKG) (OTC PINK: EKGGF) ("CardioComm Solutions" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, today announced a partnership with CareSpan USA Inc., a leading provider of digital healthcare delivery systems, entered into on April 21, 2017. Under the agreement, the parties have agreed to integrate CardioComm's cloud-based electrocardiogram ("ECG") analysis tools into CareSpan's Virtual Clinic. This integration of CardioComm's web-based FDA-cleared tools sets a new benchmark standard for the remote analysis of 1, 3, and 12 lead ECG data for online patient care.
CardioComm's newly integrated ECG features expand on CareSpan's existing ECG data display to include real-time visualization and measurement of the QRS complex of graphical deflections seen on a patient's ECG, the annotation of the data for each lead, the variable scaling of rhythms, and the filtering of data to rapidly identify anomalies in the signals.
The CareSpan Clinic is the first online digital healthcare delivery system that meets and exceeds the standards of an in-person ambulatory care encounter, integrating patient-provider video telepresence, vital signs capture, medical imaging, heart/breathing sounds, ECG, e-prescribing, specialist consultations, and a mobile patient health record, all managed within a clinical workflow system. Unlike typical "video-only" telemedicine systems, CareSpan provides all the essential resources for physicians to diagnose and prescribe to patients with chronic health conditions and multiple comorbidities.
The ECG data collected in the CareSpan patient medical record can be easily compared to previous readings and interpreted by remote cardiologists as part of an online exam. All data collected during a CareSpan exam is available for analytics applications to further enhance interpretation of cardiac functions by a patient's healthcare provider. As is the case with CareSpan itself, the CardioComm display panel only requires a standard web browser.
"CardioComm is clearly the leading technology for ECG analysis, and the only high quality resource we've found that offers cloud-based tools that we can easily integrate with our own cloud-based platform," said Mark Winter, CEO of CareSpan. "CardioComm's ECG module, combined with our interactive exam framework, offers physicians and specialists capabilities that far exceed what are available commercially, even in the most expensive and complex EHR's in hospital settings."
CardioComm's focus is on making cardiac health data available for a new generation of digital healthcare delivery technologies, such as CareSpan. "CardioComm has designed GEMS™ Flex, our newest ECG analysis solution, with systems like CareSpan's in mind. It was clear that the more advanced telemedicine offerings would evolve beyond the video-only paradigm that is not focused on diagnostic data," said Etienne Grima, CEO of CardioComm. "As we develop new interfaces for next generation ECG products that are coming to market, CareSpan will be able to easily integrate the data from new products in its state-of-the-art virtual clinic," he added.
The expanded CardioComm ECG analysis functions will be available within the CareSpan Virtual Clinic starting in June 2017. All current CareSpan customers will have immediate access to these tools and support at that time.
About CareSpan USA, Inc.
CareSpan is the only digital healthcare system that meets and often exceeds the standards of an in-person exam for care delivered over the Internet. Physicians and other providers enjoy lower operational costs, greater flexibility in clinician utilization and increased access to new patients. Insurers benefit from lower total care delivery costs, with better case management and outcomes. Patients receive access to high quality healthcare that is affordable, and fulfills their expectation of care continuity regardless of their location. Please visit www.carespanhealth.com for more information.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Mark Winter; Chief Executive Officer
(303) 800-8296 ext: 105
[email protected]
About CardioComm Solutions, Inc.
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing, and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada. Please visit http://www.cardiocomm.com for more information.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
[email protected]
Forward-Looking Statements
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: CardioComm Solutions, Inc.